Rosiglitazone induces HO-1 expression via either NOX/ROS/c-Src/Pyk2/Akt-dependent Nrf2 activation or PPARγ in human pulmonary alveolar epithelial cells (HPAEpiCs) and suppresses LPS-mediated inflammatory responses, suggesting that PPARγ agonists may be useful for protection against pulmonary inflammation [115]. Here, PPARG is linked to inflammatory response.